Emergent BioSolutions Inc - ESG Rating & Company Profile powered by AI
The Sustainability rating for Emergent BioSolutions Inc represents its reporting of the UN SDGs. The report of Emergent BioSolutions Inc leverages data from across the web as well as from available filings by Emergent BioSolutions Inc. Comprehensive Sustainability analysis of Emergent BioSolutions Inc can be accessed by signing in.
Emergent BioSolutions Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.9; made up of an environmental score of 0.0, social score of 0.0 and governance score of 2.7.
0.9
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1810 | XBiotech Inc | 1.1 | Low |
1826 | Mitsubishi Tanabe Pharma Corp | 1.0 | Low |
1827 | Emergent BioSolutions Inc | 0.9 | Low |
1827 | CannTrust Holdings Inc | 0.9 | Low |
1827 | Cannabis Poland SA | 0.9 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Emergent BioSolutions Inc have an accelerator or VC vehicle to help deliver innovation?
Does Emergent BioSolutions Inc disclose current and historical energy intensity?
Does Emergent BioSolutions Inc report the average age of the workforce?
Does Emergent BioSolutions Inc reference operational or capital allocation in relation to climate change?
Does Emergent BioSolutions Inc disclose its ethnicity pay gap?
Does Emergent BioSolutions Inc disclose cybersecurity risks?
Does Emergent BioSolutions Inc offer flexible work?
Does Emergent BioSolutions Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Emergent BioSolutions Inc disclose the number of employees in R&D functions?
Does Emergent BioSolutions Inc conduct supply chain audits?
Does Emergent BioSolutions Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Emergent BioSolutions Inc conduct 360 degree staff reviews?
Does Emergent BioSolutions Inc disclose the individual responsible for D&I?
Does Emergent BioSolutions Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Emergent BioSolutions Inc disclose current and / or historical scope 2 emissions?
Does Emergent BioSolutions Inc disclose water use targets?
Does Emergent BioSolutions Inc have careers partnerships with academic institutions?
Did Emergent BioSolutions Inc have a product recall in the last two years?
Does Emergent BioSolutions Inc disclose incidents of discrimination?
Does Emergent BioSolutions Inc allow for Work Councils/Collective Agreements to be formed?
Has Emergent BioSolutions Inc issued a profit warning in the past 24 months?
Does Emergent BioSolutions Inc disclose parental leave metrics?
Does Emergent BioSolutions Inc disclose climate scenario or pathway analysis?
Does Emergent BioSolutions Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Emergent BioSolutions Inc disclose the pay ratio of women to men?
Does Emergent BioSolutions Inc support suppliers with sustainability related research and development?
Does Emergent BioSolutions Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Emergent BioSolutions Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Emergent BioSolutions Inc involved in embryonic stem cell research?
Does Emergent BioSolutions Inc disclose GHG and Air Emissions intensity?
Does Emergent BioSolutions Inc disclose its waste policy?
Does Emergent BioSolutions Inc report according to TCFD requirements?
Does Emergent BioSolutions Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Emergent BioSolutions Inc disclose energy use targets?
Does Emergent BioSolutions Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Emergent BioSolutions Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Emergent BioSolutions Inc
These potential risks are based on the size, segment and geographies of the company.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.